Kaipharm
Seoul
About Kaipharm
KaiPharm Co., Ltd. develops unique drug virtual screening algorithm based on big data and artificial intelligence and provides comprehensive drug discovery solution. We build a multifaceted, integrated database of compound structures, drug-target relationships, drug-disease relationships, drug-induced transcriptome, and have unique data mining technologies. In-house database is the basis for developing artificial intelligence algorithms and providing complex solutions. One of the main project, KMAP, is to produce large drug-induced transcriptome by the next generation sequencing (NGS) and to find repositioning drugs. The KMAP use the method from the publicly available drug transcriptome pattern analysis (CMAP analysis), but expands the scope of analysis and increases the prediction accuracy because it not only produces proprietary data on its own, but also overcomes existing public data limitations by measuring the entire genes’ expression (21,000). We has conducted Internal researches for many years and accumulated analytical know-how. Secondly, for drug virtual screening service, we have two algorithm patents: BEAR registered in US & Korea, BACoN registered in Korea. These algorithms are unique technique that uses only large-scale drug screening data(bioactivity) without using any structural information on the compounds and targets. Uniqueness has been achieved through machine learning formula developed in-house, and the accuracy of prediction is improved by analyzing large data.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2020)
- Website: kaipharm.com
- Phone: 82-02-3277-4294
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kaipharm-154510 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.